No Data
No Data
BioCryst Pharmaceuticals Initiated at Overweight by Cantor Fitzgerald
Cantor Fitzgerald Initiates BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Announces Target Price $20
BioCryst Pharmaceuticals (BCRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
JMP Securities Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $18
BioCryst Pharmaceuticals to Report First Quarter 2025 Financial Results on May 5, 2025
BofA Securities Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $11